fig2
![Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication](https://image.oaes.cc/63cfb2de-0412-4474-b26c-4b8901b722e2/4675.fig.2.jpg)
Figure 2. LSC-specific surface markers and the different types of drug agents targeting these markers. All depicted surface markers except CD19 are differentially expressed on AML LSCs. CD19 is a marker specific for B-ALL blasts. In addition, CD7 and CD25 have also been used as targets for ALL treatment. The depicted agents have recently been used in clinical trials. Created with BioRender.com. LSC: Leukemic stem cell; AML: acute myeloid leukemia; CAR: chimeric antigen receptor; TDB: T cell-dependent bispecific; DART: dual-affinity re-targeting antibody.